5 research outputs found
Quantum Algorithm Implementations for Beginners
As quantum computers become available to the general public, the need has
arisen to train a cohort of quantum programmers, many of whom have been
developing classical computer programs for most of their careers. While
currently available quantum computers have less than 100 qubits, quantum
computing hardware is widely expected to grow in terms of qubit count, quality,
and connectivity. This review aims to explain the principles of quantum
programming, which are quite different from classical programming, with
straightforward algebra that makes understanding of the underlying fascinating
quantum mechanical principles optional. We give an introduction to quantum
computing algorithms and their implementation on real quantum hardware. We
survey 20 different quantum algorithms, attempting to describe each in a
succinct and self-contained fashion. We show how these algorithms can be
implemented on IBM's quantum computer, and in each case, we discuss the results
of the implementation with respect to differences between the simulator and the
actual hardware runs. This article introduces computer scientists, physicists,
and engineers to quantum algorithms and provides a blueprint for their
implementations
Recommended from our members
Temporal order of clinical and biomarker changes in familial frontotemporal dementia
Temporal order of clinical and biomarker changes in familial frontotemporal dementia
Unlike familial Alzheimer's disease, we have been unable to accurately predict symptom onset in presymptomatic familial frontotemporal dementia (f-FTD) mutation carriers, which is a major hurdle to designing disease prevention trials. We developed multimodal models for f-FTD disease progression and estimated clinical trial sample sizes in C9orf72, GRN and MAPT mutation carriers. Models included longitudinal clinical and neuropsychological scores, regional brain volumes and plasma neurofilament light chain (NfL) in 796 carriers and 412 noncarrier controls. We found that the temporal ordering of clinical and biomarker progression differed by genotype. In prevention-trial simulations using model-based patient selection, atrophy and NfL were the best endpoints, whereas clinical measures were potential endpoints in early symptomatic trials. f-FTD prevention trials are feasible but will likely require global recruitment efforts. These disease progression models will facilitate the planning of f-FTD clinical trials, including the selection of optimal endpoints and enrollment criteria to maximize power to detect treatment effects
Temporal order of clinical and biomarker changes in familial frontotemporal dementia
Unlike familial Alzheimer's disease, we have been unable to accurately predict symptom onset in presymptomatic familial frontotemporal dementia (f-FTD) mutation carriers, which is a major hurdle to designing disease prevention trials. We developed multimodal models for f-FTD disease progression and estimated clinical trial sample sizes in C9orf72, GRN and MAPT mutation carriers. Models included longitudinal clinical and neuropsychological scores, regional brain volumes and plasma neurofilament light chain (NfL) in 796 carriers and 412 noncarrier controls. We found that the temporal ordering of clinical and biomarker progression differed by genotype. In prevention-trial simulations using model-based patient selection, atrophy and NfL were the best endpoints, whereas clinical measures were potential endpoints in early symptomatic trials. f-FTD prevention trials are feasible but will likely require global recruitment efforts. These disease progression models will facilitate the planning of f-FTD clinical trials, including the selection of optimal endpoints and enrollment criteria to maximize power to detect treatment effects